Does the media refer more to RYTM or MRNA?

In the previous week, Moderna had 16 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 22 mentions for Moderna and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Moderna's score of 0.50 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 9 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RYTM or BNTX?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Rhythm Pharmaceuticals' score of 0.71 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or RYTM?

In the previous week, Roivant Sciences had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Roivant Sciences and 6 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.12 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSM or RYTM?

In the previous week, Insmed had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 17 mentions for Insmed and 6 mentions for Rhythm Pharmaceuticals. Insmed's average media sentiment score of 0.88 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RYTM or VTRS?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for Viatris. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Viatris' score of 0.56 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rhythm Pharmaceuticals (RYTM) Competitors

$109.84 +1.58 (+1.46%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$109.84 0.00 (0.00%)

As of 06/26/2026 07:59 PM Eastern

Compare

RYTM vs. MRNA, BNTX, ROIV, INSM, and VTRS

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? MarketBeat compares Rhythm Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rhythm Pharmaceuticals include Moderna (MRNA), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Rhythm Pharmaceuticals compare to Moderna?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Moderna had 16 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 22 mentions for Moderna and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Moderna's score of 0.50 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	9 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.3% of Moderna shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Moderna	-143.55%	-26.64%	-19.32%

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Moderna. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
Moderna	$1.94B	13.73	-$2.82B	-$8.15	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $133.13, indicating a potential upside of 21.20%. Moderna has a consensus target price of $37.13, indicating a potential downside of 44.80%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Moderna on 10 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to BioNTech?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Rhythm Pharmaceuticals presently has a consensus price target of $133.13, suggesting a potential upside of 21.20%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 42.03%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Rhythm Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A

15.5% of BioNTech shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than BioNTech. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Rhythm Pharmaceuticals' score of 0.71 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

BioNTech has a net margin of -44.39% compared to Rhythm Pharmaceuticals' net margin of -93.33%. BioNTech's return on equity of -5.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

In the previous week, Roivant Sciences had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Roivant Sciences and 6 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.12 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential downside of 1.41%. Rhythm Pharmaceuticals has a consensus price target of $133.13, indicating a potential upside of 21.20%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,966.77	-$299.77M	-$0.60	N/A
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A

Summary

Rhythm Pharmaceuticals beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 104.94%. Rhythm Pharmaceuticals has a consensus target price of $133.13, suggesting a potential upside of 21.20%. Given Insmed's stronger consensus rating and higher probable upside, research analysts clearly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Insmed had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 17 mentions for Insmed and 6 mentions for Rhythm Pharmaceuticals. Insmed's average media sentiment score of 0.88 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A

Summary

Insmed beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Viatris?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 3 mentions for Viatris. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Viatris' score of 0.56 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals presently has a consensus target price of $133.13, suggesting a potential upside of 21.20%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 7.16%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Rhythm Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Viatris has a net margin of -2.04% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Viatris' return on equity of 19.04% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Viatris	-2.04%	19.04%	7.62%

Summary

Rhythm Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.53B	$3.63B	$7.04B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.23%
P/E Ratio	-35.09	21.56	26.13	24.16
Price / Sales	39.67	334.26	556.13	101.82
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	52.81	8.33	10.78	6.36
Net Income	-$196.54M	$23.91M	$3.58B	$337.99M
7 Day Performance	13.48%	3.42%	2.22%	0.10%
1 Month Performance	20.15%	1.55%	1.12%	-0.11%
1 Year Performance	75.10%	65.22%	34.29%	27.61%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	2.5076 of 5 stars	$109.84 +1.5%	$133.13 +21.2%	+78.8%	$7.53B	$189.76M	N/A	140	Insider Trade High Trading Volume
MRNA Moderna	1.1115 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+144.3%	$25.38B	$1.94B	N/A	4,700	Trending News Analyst Forecast
BNTX BioNTech	4.2767 of 5 stars	$90.19 -0.8%	$129.56 +43.7%	-14.1%	$22.98B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.0363 of 5 stars	$31.25 -0.6%	$33.59 +7.5%	+193.7%	$22.61B	$8.26M	N/A	860	Positive News Insider Trade
INSM Insmed	3.5541 of 5 stars	$98.61 +2.9%	$211.86 +114.9%	+1.6%	$20.76B	$606.42M	N/A	1,664	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Rhythm Pharmaceuticals compare to Moderna?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. MRNA, BNTX, ROIV, INSM, and VTRS

How does Rhythm Pharmaceuticals compare to Moderna?

Does the media refer more to RYTM or MRNA?

Do insiders and institutionals believe in RYTM or MRNA?

Is RYTM or MRNA more profitable?

Which has stronger earnings and valuation, RYTM or MRNA?

Do analysts recommend RYTM or MRNA?

Which has more risk & volatility, RYTM or MRNA?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Do analysts prefer RYTM or BNTX?

Which has higher valuation & earnings, RYTM or BNTX?

Do institutionals and insiders hold more shares of RYTM or BNTX?

Does the media prefer RYTM or BNTX?

Which has more risk and volatility, RYTM or BNTX?

Is RYTM or BNTX more profitable?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Which has more risk & volatility, ROIV or RYTM?

Does the media prefer ROIV or RYTM?

Is ROIV or RYTM more profitable?

Do institutionals & insiders believe in ROIV or RYTM?

Do analysts prefer ROIV or RYTM?

Which has stronger valuation & earnings, ROIV or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Which has more volatility and risk, INSM or RYTM?

Do analysts recommend INSM or RYTM?

Does the media refer more to INSM or RYTM?

Is INSM or RYTM more profitable?

Which has higher valuation and earnings, INSM or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Which has more risk and volatility, RYTM or VTRS?

Do insiders & institutionals hold more shares of RYTM or VTRS?

Which has better valuation & earnings, RYTM or VTRS?

Does the media refer more to RYTM or VTRS?

Do analysts recommend RYTM or VTRS?

Is RYTM or VTRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools